Evidence map›Paper›PMID 40673987›Full record

ArticleClinical and experimental medicine2025

DEK facilitates bortezomib resistance of multiple myeloma by modulating ferroptosis.

Huiquan Wang, Jiafeng Zhang, Lei Chen, Hefei Ren, Chang Liu, Hong Kun Wu, Huiying Qiu, Juan Lu, Lin Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Huiquan Wang *Department of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Jiafeng Zhang *Department of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Lei Chen *Department of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Hefei RenDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Chang LiuDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Hong Kun WuDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Huiying QiuDepartment of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. qiuhy5@126.com.
Juan LuContinuing Education Centre, Naval Medical University (Second Military Medical University), 800 Xiangyin Road, Shanghai, 200433, China. lujuan506@sina.com.
Lin ZhouDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China. lynnzhou36@126.com.

Funding

National Natural Science Foundation of China 82402695, 82372313, 82272390, 82102482, 82072371
6 · The paper itself

Abstract

Multiple myeloma (MM) ranks as the second most prevalent blood cancer. In the treatment of MM, resistance to proteasome inhibitors like bortezomib (BTZ) is a significant issue, and the primary regulators and mechanisms are still not completely explored. As a result, this investigation aimed to uncover essential genes and mechanisms contributing to BTZ resistance in MM. Out of 359 differentially expressed genes, DEK oncogene (DEK) was pinpointed as the key drug-resistance gene in MM through bioinformatic analysis and was found to be overexpressed in MM patients. DEK was overexpressed in BTZ-resistant cell lines, enhancing the resistance of MM cells to bortezomib. Also, the depletion of DEK mitigated bortezomib resistance in MM cells by initiating ferroptosis. The findings indicated a novel role of DEK in the resistance of MM to bortezomib, which could inform new treatment strategies for BTZ-resistant MM.

Indexed as

BortezomibChromosomal Proteins, Non-HistoneDrug Resistance, NeoplasmFerroptosisMultiple MyelomaOncogene ProteinsPoly-ADP-Ribose Binding ProteinsAntineoplastic AgentsCell Line, TumorGene Expression Regulation, NeoplasticHumansAntineoplastic AgentsBortezomibChromosomal Proteins, Non-HistoneDEK protein, humanOncogene ProteinsPoly-ADP-Ribose Binding Proteinsdrug resistanceferroptosisHematological diseaseMultiple myeloma

Identifiers

PMID40673987
PMCPMC12271269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.